Study of zigakibart for IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called zigakibart for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have IgA nephropathy confirmed by a kidney biopsy in the last 5 years.
- Your kidney function (eGFR) is 45 or higher.
- You have protein in your urine that is at least 0.5 grams per day or a urine protein-to-creatinine ratio of at least 0.5.
- You weigh at least 45 kg (99 pounds) and your BMI is 35 or lower.
- You have not taken certain immune-suppressing drugs or other investigational treatments for IgA nephropathy in the past 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Felzartamab (given as an infusion) for people with IgA nephropathy (IgAN), a kidney disease. The goal is to see if it can reduce protein leaking into urine and protect kidney function.
This trial tests a new drug called cizutamig for people with IgA nephropathy who still have high protein in their urine despite trying other treatments. It aims to see if the drug can help protect kidney function.
This trial tests an experimental medication (ARGX-121) to see if it can reduce protein in your urine, which is a sign of kidney damage in IgA nephropathy. If you qualify, you may receive the study drug and help researchers learn if it's safe and effective.
This study is for people with IgA nephropathy who completed a previous zigakibart study. It tests whether continuing treatment with zigakibart (given as a shot every two weeks) is safe and helpful over a longer period.
This trial tests two study medicines, zigakibart and atrasentan, together for adults with a kidney disease called IgA nephropathy. The goal is to see if this combination helps protect kidney function and reduces protein in the urine.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Hear when a new Immunoglobulin A Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.